Kayla Marsh
University of Wyoming · 208 works · 695 citations · h-index 7
Top works
- Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Integrated analysis of cell-free DNA for the early detection of cancer in people with Li-Fraumeni Syndrome
- Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer
- Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients.
- Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy
- Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
- The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative
- Methylated circulating tumor DNA (cfMeDIP) as a predictive biomarker of clinical outcome in pan-cancer patients (pts) treated with pembrolizumab (P).
- Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer phase I IO cohort
- Table S1 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
- Data from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
- Supplementary Figure S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
- Figure S7 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
- Supplementary Figure 8 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Figure S1 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
- Supplementary Table S3 from Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression
- Supplementary Figure S6 from Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression